PDF(Pubmed)
Abstract：
OBJECTIVE: Tumor hypoxia induces the production of Hypoxia-Inducible Factor (HIF)-1 alpha, which interacts with NF-kB, leading to cancer proliferation and metastasis. This study investigated the effect of tumor hypoxia modulation using carbogen (95% O2 and 5% CO2) and nicotinamide on reducing soluble interleukin-2 receptor (sIL-2R) levels in newly diagnosed DLBCL patients with tissue overexpression of HIF-1α ≥10%.
METHODS: A prospective randomized controlled clinical trial was conducted at Dr. Kariadi Hospital in Semarang, Indonesia, from 2021 to 2022. Newly diagnosed DLBCL patients with tissue HIF-1α ≥10% were randomized into an intervention group (nicotinamide 2,000 mg + carbogen 10 liters/min during R-CHOP) and a control group (R-CHOP alone) for one cycle. sIL-2R levels were measured in the blood before and after intervention.
RESULTS: The intervention group showed a significant reduction in sIL-2R levels after chemotherapy (p=0.026), with 85% of samples exhibiting a decrease. In contrast, only 45% of samples in the control group demonstrated a decrease in sIL-2R levels (p=0.184). The median sIL-2R level decreased from 139.50 pg/mL to 70.50 pg/mL in the intervention group, while the control group exhibited an increase from 182.50 pg/mL to 250.00 pg/mL following one cycle of chemotherapy.
CONCLUSIONS: Tumor hypoxia modulation led to a significant decrease in serum sIL-2R levels, potentially through improvements in the crosstalk between hypoxia and inflammation pathways.
METHODS: A prospective randomized controlled clinical trial was conducted at Dr. Kariadi Hospital in Semarang, Indonesia, from 2021 to 2022. Newly diagnosed DLBCL patients with tissue HIF-1α ≥10% were randomized into an intervention group (nicotinamide 2,000 mg + carbogen 10 liters/min during R-CHOP) and a control group (R-CHOP alone) for one cycle. sIL-2R levels were measured in the blood before and after intervention.
RESULTS: The intervention group showed a significant reduction in sIL-2R levels after chemotherapy (p=0.026), with 85% of samples exhibiting a decrease. In contrast, only 45% of samples in the control group demonstrated a decrease in sIL-2R levels (p=0.184). The median sIL-2R level decreased from 139.50 pg/mL to 70.50 pg/mL in the intervention group, while the control group exhibited an increase from 182.50 pg/mL to 250.00 pg/mL following one cycle of chemotherapy.
CONCLUSIONS: Tumor hypoxia modulation led to a significant decrease in serum sIL-2R levels, potentially through improvements in the crosstalk between hypoxia and inflammation pathways.
摘要：
目的：肿瘤缺氧诱导产生缺氧诱导因子（HIF）-1α，与NF-kB相互作用，导致癌症增殖和转移。本研究探讨了使用碳原（95％O2和5％CO2）和烟酰胺调节肿瘤缺氧对降低HIF-1α≥10％组织过表达的新诊断DLBCL患者可溶性白介素2受体（sIL-2R）水平的影响。
方法：在三宝廊的Kariadi医生医院进行了一项前瞻性随机对照临床试验，印度尼西亚,从2021年到2022年。将组织HIF-1α≥10％的新诊断DLBCL患者随机分为干预组（R-CHOP期间烟酰胺2,000mg碳原10升/分钟）和对照组（仅R-CHOP），为期一个周期。在干预前后测定血液中sIL-2R水平。
结果：干预组化疗后sIL-2R水平显着降低（p=0.026），85%的样品表现出下降。相比之下,对照组中只有45%的样本显示sIL-2R水平降低(p=0.184).干预组sIL-2R中位数从139.50pg/mL下降到70.50pg/mL,而对照组在一个周期的化疗后表现出从182.50pg/mL增加到250.00pg/mL。
结论：肿瘤缺氧调制导致血清sIL-2R水平显著下降，可能通过改善缺氧和炎症途径之间的串扰。
方法：在三宝廊的Kariadi医生医院进行了一项前瞻性随机对照临床试验，印度尼西亚,从2021年到2022年。将组织HIF-1α≥10％的新诊断DLBCL患者随机分为干预组（R-CHOP期间烟酰胺2,000mg碳原10升/分钟）和对照组（仅R-CHOP），为期一个周期。在干预前后测定血液中sIL-2R水平。
结果：干预组化疗后sIL-2R水平显着降低（p=0.026），85%的样品表现出下降。相比之下,对照组中只有45%的样本显示sIL-2R水平降低(p=0.184).干预组sIL-2R中位数从139.50pg/mL下降到70.50pg/mL,而对照组在一个周期的化疗后表现出从182.50pg/mL增加到250.00pg/mL。
结论：肿瘤缺氧调制导致血清sIL-2R水平显著下降，可能通过改善缺氧和炎症途径之间的串扰。
